Johnson & Johnson: here are all the cases in which the single-dose vaccine is preferable (according to the Ministry of health)

They are the over 60s and the so-called non-permanent people, that is, those who often move or are difficult to reach for work.

Don't store avocado like this: it's dangerous

News comes from the Ministry of Health regarding the Johnson & Johnson single-dose vaccine. Taking into account the opinion of the Scientific Technical Committee, the Ministry has issued a new circular indicating the cases in which Janssen can be administered: they are the over 60s and the so-called non-permanent people, i.e. those who often move or are difficult for work. to reach.

A question that in recent weeks, after the stop at Astrazeneca the under 60s (even for the second doses), many have asked themselves. Would the fate of Janssen have been similar? Answering this question was the circular issued yesterday. Specifically, the paper illustrated both the completion of the vaccination cycle in the under 60s who received a first dose of Vaxzevria vaccine, formerly Astrazeneca, both gods clarification on how to use the Janssen vaccine. 

The Ministry's clarification starts from the assumption that Janssen is recommended for over 60s, but if you consider the benefit-risk ratio, it could also be favorable for people under 60 who travel a lot.

The CTS has also provided for the possibility that specific situations arise in which the advantageous conditions of the single administration are evident, and that in the absence of other options, the Janssen vaccine should preferentially be used, subject to the opinion of the territorially competent Ethics Committee. In particular, the vaccine in question could be administered in certain circumstances, such as in the case of specific vaccination campaigns for non-resident populations and / or characterized by high work mobility and, more generally, for the so-called groups of hard to reach population. In fact, in these circumstances, already indicated by the CTS, considering the criticalities relating to the logistics and timing of the administration of a two-dose vaccination cycle, the benefit / risk ratio administration of the Janssen vaccine in individuals under the age of 60 could result favorable,

reads the circular published on 18 June 2021.

The other category for which it is recommended is that of over 60s, also in light of the opinion sent on 11 June last, on the basis of which it is

recommended the Janssen vaccine for subjects over 60 years of age, also in the light of what was defined by the Technical Scientific Commission of Aifa.

Being an adenoviral vaccine like AstraZeneca, the same precautionary principle also applies to J&J to avoid the rare risk of thrombosis in the younger population. 

Sources of reference: Ministry of Health

READ also:

  • Stop Astrazeneca to under 60, but what to do with the Johnson & Johnson vaccine?
  • How rare are blood clots after the AstraZeneca vaccine? What should you pay attention to? And how are they treated?
add a comment of Johnson & Johnson: here are all the cases in which the single-dose vaccine is preferable (according to the Ministry of health)
Comment sent successfully! We will review it in the next few hours.